in Myanmar to offer cord blood banking and cord lining services in October 2016. First in Southeast Asia to be dual-accredited by world-class quality standards: AABB and Fact-Netcord in January 2016. First Cord Blood Bank to be named as one of the Best "Under A Billion" Companies by Forbes Asia in 2015. First in Singapore to win Frost & Sullivan Singapore Stem Cell Company of the Year Award in October 2015. 2014–2012 Launched non-invasive newborn metabolic screening (Metascreen) in Hong Kong, Indonesia and the Philippines. Extended its strategic alliance and co-operation with CordLabs Asia Pte. Ltd. and CCBC in relation to the provision of human postnatal cord lining storage services to certain territories in the People's Republic of China in March 2014 Acquired a 19.92% stake in StemLife in October 2013, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad. Signed a non-binding term sheet with NYSE-listed China Cord Blood Corporation to jointly explore and develop new services based on cellular technologies in November 2013 The Group's Indian subsidiary, Cordlife Sciences (India) Pvt. Ltd., introduced a metabolic screening service known as Metascreen in October 2013 Signed a non-binding Memorandum of Understanding with Golden Meditech Holdings Limited in respect of a proposed joint venture in the Shanghai Free Trade Pilot Zone in October 2013 Launched provision of cord lining banking services in Singapore in May 2013 under its wholly owned subsidiary, Cordlife Technologies Pte Ltd. India facility accredited by AABB in July 2013 Completed the acquisition of the cord blood and cord lining banking businesses and assets in India, the Philippines, Hong Kong and Indonesia from Australia-listed Life Corporation Limited (formerly known as Cordlife Limited) in June 2013 Cordlife moved to its fully owned, 23,000 square feet office and laboratory facility in A'Posh Bizhub, Yishun Acquired 10% of CCBC and disposed 10% indirect equity stake in Guangzhou Tianhe Nuoya in December 2012 Listed on Mainboard of SGX-ST on March 29, 2012 2011–2008 Released a cord blood unit for treatment of neuroblastoma in Hong Kong in January 2011 Launched provision of cord lining banking services in Hong Kong in March 2011 Cordlife demerged from Cordlife Limited on June 30, 2011; entered into Rights Of First Refusal (ROFR) agreement to acquire relevant businesses in Indonesia, the Philippines and India Hong Kong facility accredited by AABB in October 2011 Released a cord blood unit for treatment of neuroblastoma in Singapore